Spray Dried ID93+GLA-SE

Stage of Development

Proof of Concept – Animal Model

Vaccine Platform

Protein / Adjuvant

Candidate Overview

AAHI’s tuberculosis vaccine candidate includes a recombinant fusion subunit protein antigen, ID93, formulated with GLA-SE, a squalene emulsion containing the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA). The vaccine candidate was developed on AAHI’s formulation (adjuvant and delivery vehicle) vaccine platform.

Sponsor / Lead Developer: Access to Advanced Health Institute (AAHI)

Development partner(s): National Institute of Health/National Institute of Allergy and Infectious Diseases (NIAID)

Primary Indication: Prevention of TB disease

Other Indication(s): Immunotherapy/Improving TB Cure Rates, Immunotherapy/Shortening TB treatment, Prevention of Mtb infection or sustained infection, and Prevention of TB recurrence

Target Population(s): Adolescents, Adults, Elderly, and To be determined

Target Route of Administration: Aerosol

Primary endpoint: Prevention of TB disease

Immune tissue localization: Lung

Immunological responses: B-cell/Antibody and T-cell

Preclinical Animal Models: Mouse

Additional Immunologic Response Information

Immune ResponseB-cell/Antibody
Characteristics of B-cell responseMucosal IgA
T-cell phenotypeCD4
T-cell functional profileIFN-γ
Preferential immune tissue localizationLung
Trained immunityNo